Australian Firm With BARDA Contract Begins Skin Patch COVID Vaccine Trial

By Jessica Karins / November 11, 2022 at 5:54 PM
A Phase I clinical trial has begun for a COVID-19 vaccine patch developed by biotechnology company Vaxxas, which could become the first needle-free COVID vaccination option. The initial trial will have a small sample size of 44 participants. Vaxxas, based in Brisbane, Australia, announced it was beginning the trial Tuesday, Nov. 8 . The study is taking place in Australia at the University of the Sunshine Coast’s Sippy Downs clinical research location. Vaxxas is also developing patch vaccines for other...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.